罗妥木单抗
化合物
罗妥木单抗（INN：Robatumumab；开发代号：SCH 717454和MK-7454）是默克和先灵葆雅生产的单克隆抗体和抗肿瘤药物。它与CD221（或称胰岛素样生长因子1受体）结合。[1]
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目標 | CD221 |
| 臨床資料 | |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 934235-44-6  |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6418H9960N1732O1992S42 |
| 摩尔质量 | 144,602.93 g·mol−1 |
参考资料
- ^ "robatumumab", p. 337 in: Quality Assurance and Safety of Medicines. Encrenaz C , 编. Proposed International Nonproprietary Names: List 100 (PDF). WHO Drug Information. 2008, 22 (4): 311–67 [2024-01-24]. （原始内容存档 (PDF)于2022-01-20）.
- ^ Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, et al. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatric Blood & Cancer. October 2016, 63 (10): 1761–70. PMC 5129487
. PMID 27362300. doi:10.1002/pbc.26087.
- ^ Clinical trial number NCT00551213 for "A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)" at ClinicalTrials.gov
- ^ Robatumumab. Adis Insight. Springer Nature Switzerland AG. [2024-01-24]. （原始内容存档于2024-01-24）.
